Loading...
Loading...
BNTX| Name | Value |
|---|---|
| Revenues | 4,278.3M |
| Cost of Revenue | 693.3M |
| Gross Profit | 3,585.0M |
| Operating Expense | 292.1M |
| Operating I/L | 3,292.9M |
| Other Income/Expense | -120.3M |
| Interest Income | 38.8M |
| Pretax | 3,172.6M |
| Income Tax Expense | 893.9M |
| Net Income/Loss | 2,278.7M |
BioNTech SE is a biotechnology company specializing in the development and commercialization of immunotherapies for cancer and infectious diseases. The company's product pipeline includes a range of immunotherapy candidates in various stages of clinical trials, targeting cancers such as melanoma, prostate cancer, head and neck cancers, breast cancer, ovarian cancer, and non-small cell lung cancer. Additionally, BioNTech is developing prophylactic vaccines for COVID-19 and influenza, as well as infectious disease immunotherapies and rare disease protein replacement therapies. The company generates revenue through collaborations with leading pharmaceutical companies and the advancement of its diverse product portfolio.
